- Home
- BLRX vs CALC Comparison
BLRX vs CALC Comparison
Compare BLRX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CALC
- Stock Information
- Founded
- BLRX 2003
- CALC 2011
- Country
- BLRX Israel
- CALC United States
- Employees
- BLRX 28
- CALC N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- CALC Health Care
- Exchange
- BLRX Nasdaq
- CALC Nasdaq
- Market Cap
- BLRX 17.2M
- CALC 48.1M
- IPO Year
- BLRX 2011
- CALC N/A
- Fundamental
- Price
- BLRX $4.04
- CALC $3.17
- Analyst Decision
- BLRX Strong Buy
- CALC Strong Buy
- Analyst Count
- BLRX 2
- CALC 2
- Target Price
- BLRX $19.00
- CALC $14.50
- AVG Volume (30 Days)
- BLRX 33.6K
- CALC 63.4K
- Earning Date
- BLRX 08-14-2025
- CALC 11-12-2025
- Dividend Yield
- BLRX N/A
- CALC N/A
- EPS Growth
- BLRX N/A
- CALC N/A
- EPS
- BLRX N/A
- CALC N/A
- Revenue
- BLRX $17,251,000.00
- CALC N/A
- Revenue This Year
- BLRX N/A
- CALC N/A
- Revenue Next Year
- BLRX N/A
- CALC N/A
- P/E Ratio
- BLRX N/A
- CALC N/A
- Revenue Growth
- BLRX 1.19
- CALC N/A
- 52 Week Low
- BLRX $2.30
- CALC $1.42
- 52 Week High
- BLRX $26.80
- CALC $5.65
- Technical
- Relative Strength Index (RSI)
- BLRX 55.55
- CALC 53.86
- Support Level
- BLRX $3.42
- CALC $3.00
- Resistance Level
- BLRX $4.36
- CALC $3.73
- Average True Range (ATR)
- BLRX 0.26
- CALC 0.31
- MACD
- BLRX 0.07
- CALC 0.04
- Stochastic Oscillator
- BLRX 65.96
- CALC 46.67
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.